Article
Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects.
Gene therapy - 1 Jul 2005
Pochampally R R, Horwitz E M, DiGirolamo C M, Stokes D S, Prockop D J
Abstract excerpt
Gene therapy for dominant-negative disorders presents a more difficult challenge than gene therapy for recessive disorders, since even partial replacement of a protein for a recessive disorder can reverse symptoms. Osteogenesis imperfecta (OI) has frequently served as a model disorder for dominant-negative defects of structural proteins. The disease is caused by mutations in type I collagen (COL1A1), the major...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.